BIVI Cuong V. Do bought BIOVIE INC. shares — SEC Form 4BUYBIOVIE INC.

The stock has surged 66.92% over the last 30 days, trading at $2.17, which is 158.43% above its 52-week low of $0.8397 but still down 42.21% from its high of $3.755.

• •Top-line results from the Phase 2 SUNRISE-PD trial for Parkinson's disease are expected in the third quarter.
• •Top-line data from the Phase 2 ADDRESS-LC Long COVID trial is expected later this summer.
• •The company is advancing bezisterim toward a pivotal Phase 3 trial following positive Phase 2 results.

• •The stock is highly volatile with a beta of 0.667, and recent news indicates that Phase IIb Parkinson's trial data was met with skepticism.
• •Short interest remains elevated at 14.91% of the float, indicating significant bearish sentiment.